Welcome to our dedicated page for VERADERMICS SEC filings (Ticker: MANE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERADERMICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERADERMICS's regulatory disclosures and financial reporting.
Suvretta Capital Management and affiliated Averill funds filed a Schedule 13D reporting significant ownership in Veradermics, Inc. common stock following its initial public offering. Suvretta Capital and Aaron Cowen may be deemed to beneficially own 4,168,991 shares, representing 11.9% of the common stock, based on 35,077,084 shares outstanding as indicated in the Final Prospectus on February 4, 2026.
The position was built through private purchases of Series B and Series C preferred stock in 2024 and 2025, which converted into common shares at a 1-for-10.067 ratio, plus substantial purchases in the initial offering at $17.00 per share and subsequent open-market buys.
The funds state they hold Veradermics for investment purposes but may buy more or sell shares depending on factors such as business prospects and market conditions. They benefit from investor registration rights and are subject to lock-up agreements restricting transfers for 180 days after February 3, 2026.
SR One Capital–affiliated funds filed a Schedule 13D disclosing a 6.4% stake in Veradermics, Inc. common stock. The funds collectively own 2,401,868 shares of Veradermics’ Common Stock following the company’s initial public offering of 17,339,294 shares at $17.00 per share.
SR One Fund II Aggregator holds 1,621,121 shares and AMZL holds 780,747 shares, largely from the automatic conversion of Series C preferred stock at a 10.067‑for‑1 ratio plus IPO purchases. The filing states the shares were acquired for investment purposes, using fund working capital without borrowing, and outlines registration rights and a 180‑day IPO lock‑up restricting sales and hedging transactions.
Veradermics, Inc. reported multiple insider share purchases by major holders linked to Suvretta Capital Management, LLC over several days in early February 2026. These indirect open‑market transactions involved common stock at prices in the mid‑$30s per share.
On February 4, 2026, reported indirect purchases included 53,344 shares of common stock at $37.11 per share, bringing one reported indirect position to 3,604,141 shares. Additional indirect buys continued on February 5 and 6, 2026, including 19,338 shares at $36.55 per share, after which one indirect holding stood at 520,453 shares.
Suvretta Capital Management, LLC and affiliated reporting persons disclosed their initial insider holdings in Veradermics, Inc. common stock. As of February 4, 2026, they indirectly beneficially owned 3,515,458 shares of common stock and an additional 370,859 shares, both reported as indirect ownership.
The filing is an initial statement of beneficial ownership, not a report of new share purchases or sales.
Veradermics, Inc. director Katarina Pance received a grant of stock options for 43,000 shares of common stock on February 3, 2026. The options carry an exercise price of $17 per share and are held as a direct ownership position.
The award was reported as an acquisition under a grant or award transaction code. According to the terms, the option will become fully vested and exercisable on February 3, 2027, which is the first anniversary of the vesting commencement date.
Veradermics, Inc. director Jane M. Grant-Kels reported acquiring equity through an option grant and a preferred stock conversion. On February 3, 2026, she received a stock option for 51,525 shares of common stock at an exercise price of $17 per share, which will be fully vested and exercisable on February 3, 2027.
On February 5, 2026, 2,455 shares of Series A Convertible Preferred Stock automatically converted into 2,455 shares of common stock on a 10.067-for-1 basis, without additional payment, immediately before the closing of Veradermics’ initial public offering, leaving her with 2,455 common shares held directly.
Veradermics, Inc. reported that director David Matthew Friedman was granted a stock option covering 43,000 shares of common stock at an exercise price of $17 per share on February 3, 2026. The option is scheduled to become fully vested and exercisable on February 3, 2027.
According to the disclosure, Friedman, an employee of Suvretta Capital Management, LLC, is holding this award for the benefit of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd. He disclaims beneficial ownership of the option, while the Funds and Suvretta Capital may be deemed to have an indirect pecuniary interest through rights to receive director compensation linked to his board service.
Veradermics, Inc. director Vladimir Coric reported multiple equity-acquiring transactions in connection with the company’s initial public offering. On February 5, 2026, Series A, B, and C convertible preferred shares automatically converted into common stock on a 10.067-for-1 basis immediately before the IPO closing.
These conversions resulted in common stock holdings shown at 33,706 shares from Series A, 148,794 from Series B, and additional common shares from Series C, split between direct ownership and entities referenced in the footnotes. Through the Vladimir Coric Family Trust 2013 and the Vladimir Coric Marital Trust 2013, indirect positions increased via these conversions.
On February 5, 2026, the trusts also executed an open-market purchase of 58,823 shares of common stock at $17 per share, bringing indicated indirect common stock holdings to 319,398 shares. Separately, on February 3, 2026, Coric received a stock option grant covering 51,525 shares at a $17 exercise price, which becomes fully vested and exercisable on February 3, 2027.
Veradermics, Inc. director John W. Childs reported multiple equity transactions tied to the company’s initial public offering. On February 5, 2026, entities associated with him converted Series A, B and C convertible preferred stock into Veradermics common shares on a 10.067-for-1 basis, resulting in 480,269, 906,862 and 520,758 common shares, respectively, all held indirectly through J.W. Childs Associates (FL), L.P. The same day, that entity also made an indirect open-market purchase of 294,117 common shares at $17 per share, bringing total indirect common stock holdings to 2,202,006 shares. Separately, on February 3, 2026, Childs received a direct stock option grant for 51,525 shares at a $17 exercise price, which becomes fully vested and exercisable on February 3, 2027.
Veradermics, Inc. reported insider activity by affiliated 10% owners on February 5, 2026. Investment funds Longitude Venture Partners V, L.P. and Longitude 103.8 East, L.P., through their general partner entities, converted existing Series B and Series C Convertible Preferred Stock into common stock in connection with Veradermics’ initial public offering, at a 10.067-for-1 conversion ratio without additional consideration.
The same affiliated entities also made indirect open-market or private purchases of Veradermics common stock at $17 per share, acquiring 192,647 shares in one account and 882,353 shares in another. Following these transactions, they reported multi-million-share indirect common stock holdings, while their managing entities and individuals disclaim beneficial ownership beyond their pecuniary interests.